MSKCC in the News: August 23 – September 6

  • Dr. Paul Glare of MSKCC commented in an article published by International Business Times about possible limitations of a new scoring system called the Prognosis in Palliative Care Study (PiPS) predictor model that might be able to inform patients in the final stages of cancer of how much time they have left so they can prepare for their passing.
  • Allan Halpern of MSKCC is quoted in a Washington Post article about a quiz from Consumer Reports on skin cancer.
  • Jed Wolchok of MSKCC announced the approval by the FDA of vemurafenib for metastatic melanoma.

Cancer Research News: August 17 – August 31

  • Pfizer’s new lung cancer pill, crizotinib (Xalkori), was approved by the FDA, and is intended to treat patients with non-small cell lung cancer and the ALK gene.
  • Michigan State researchers have created Gene-Z, a device that works with an iPod Touch or Android tablet to analyze microRNAs to detect cancer quickly and cheaply.
  • A British cancer survival scale for patients in palliative care reliably predicted whether a patient had days, weeks, or months left to live.